Jonathan Davis, MD
Advanced Heart Failure and Transplant Cardiology · Saint Louis, MONPI 1538303276
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.3%), consulting fees and education — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 69.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $1,074 and has fallen 71.2% since, to $309 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in MO, where the typical reported total is $7,967.
Across 21 payments — averaging $110.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Abbott$371
- Abiomed$110
- Kestra Medical Technology Services, Inc.$84
- Esperion Therapeutics, Inc.$40
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$30
- plus $71 from 3 others
Across 2 payments — averaging $31,354 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$63K
What the payments were for
- Consulting fees$1,07446%
- Food & beverage$1,20852%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $1,605 |
| Abbott | 3 | $371 |
| Abiomed | 1 | $110 |
| Kestra Medical Technology Services, Inc. | 2 | $84 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $30 |
| Boehringer Ingelheim | 1 | $30 |
| Edwards Lifesciences | 1 | $22 |
| Pfizer | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,074
- MitraClip System$141
- GALLANT$124
- HeartMate 3 Left Ventricular Dev$106
How this compares
$2,312 in reported general payments places this provider in the 20th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
See all advanced heart failure and transplant cardiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 319 | $302,549 |
| JardianceEmpagliflozin | 328 | $273,853 |
| EliquisApixaban | 109 | $94,703 |
| FarxigaDapagliflozin Propanediol | 83 | $72,608 |
| XareltoRivaroxaban | 78 | $65,542 |
| OzempicSemaglutide | 26 | $32,339 |
| VerquvoVericiguat | 28 | $21,141 |
| DapagliflozinDapagliflozin Propanediol | 28 | $14,160 |
| Metoprolol Succinate | 345 | $5,719 |
| Bumetanide | 65 | $2,739 |
| Atorvastatin Calcium | 344 | $2,315 |
| Spironolactone | 331 | $1,626 |
| Eplerenone | 22 | $1,560 |
| PaceroneAmiodarone Hcl | 11 | $1,335 |
| Ezetimibe | 27 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $30 | $273,853328 claims |
| PfizerEliquis | $19 | $94,703109 claims |
| AstraZenecaFarxiga | $1,605 | $72,60883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
Other advanced heart failure and transplant cardiology in Saint Louis
- Gregory EwaldSaint Louis$35K
- Sumanth PrabhuSaint Louis$35K
- Nancy SweitzerSaint Louis$32K
- Justin HartupeeSaint Louis$30K
- Kory LavineSaint Louis$12K
- Justin VaderSaint Louis$8K
- Jonathan MorenoSaint Louis$5K
- Amanda VermaSaint Louis$5K
- Ali JavaheriSaint Louis$4K
- Edward GeltmanSaint Louis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.